The clinical observation of bevacizumab intravitreal injection as adjunctive treatment for laser coagulation to treat retinopathy of prematurity

( views:147, downloads:0 )
Author:
ZHANG Guo-ming(Shenzhen Eye Hospital of Second Clinical Medical College of J inan University ,Shenzhen 518040, China)
TANG Song(Shenzhen Eye Hospital of Second Clinical Medical College of J inan University ,Shenzhen 518040, China)
ZENG Jian(Shenzhen Eye Hospital of Second Clinical Medical College of J inan University ,Shenzhen 518040, China)
()
()
()
()
()
()
Journal Title:
Chinese Journal of Ocular Fundus Diseases
Issue:
Volume 28, Issue 01, 2012
DOI:
Key Word:
Retinopathy of prematurity/drug therapy;Laser coagulation;Antibodies,monoclonal/therapeutic use;Vascular endothelial growth factors

Abstract: Objective To observe the application and effectiveness of bevacizumab intravitreal injection as adjunctive treatment for laser coagulation to treat retinopathy of prematurity (ROP).Methods From March 2008 to October 2010,17 infants (31 eyes) with ROP received bevacizumab intravitreal injection and were analyzed.Ten infants were male (18 eyes) and 7 were female (13 eyes).Their gestational age was from 24.7 to 31.0 weeks,with a mean of (28.2±1.9) weeks.Their birth weight was from 750 to 1600 grams,with a mean of (1150 ± 264) grams.The indications for treatment included poor papillary dilation and refractive media opacity precluding complete laser coagulation and that ROP could not be controlled after complete laser coagulation treatment.The duration of follow-up was 1.4 to 40.8 months,with a mean of (20.8±13.2) months.It was noted whether the diseases were completely controlled or not,unfavourable structural outcome occurred or not and if there were complications regarding treatment.Results During the follow-up of all 31 eyes,ROP of 27 eyes (87.0%) was controlled by bevacizumab intravitreal injection as adjunctive treatment for laser coagulation. Increasing neovascularization and traction retinal detachment occurred in 2 eyes (6.5 %).These 2 eyes underwent vitreoretinal surgery.The posterior retinal structure returned to normal in 1 eye and posterior vitreoretinal traction occurred in 1 eye.After bevacizumab intravitreal injection ROP continued progressing and traction retina detachment occurred in 2 eyes.The overall health of this infant remained good during and after operation.No systemic adverse drug reactions were found.No endophthalmitis occurred. No ocular complications such as corneal burn,cataract,and anterior segmental ischemia were found.Conclusions During the follow-up,the effectiveness of bevacizumab intravitreal injection as adjunctive treatment for laser coagulation to treat ROP was positive. No complications regarding the treatment were found.

  • [1]Salvin JH,Lehman SS,Jin J,et al.Update on retinopathy of prematurity: treatment options and outcomes. Curr Opin Ophthalmol,2010,21:329-334.
  • [2]Early Treatment for Retinopathy of Prematurity Cooperative Group.Revised indications for the treatment of retinopathy of prematurity:results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol, 2003,121:1684-1694.
  • [3]Flynn JT, Chan-Ling T. Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease.Am J Ophthalmol,2006,142:46-59.
  • [4]Lalwani GA,Berrocal AM,Murray TG,et al.Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.Retina,2008,28:13-18.
  • [5]Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.N Engl J Med,2011,364:603-615.
  • [6]Quiroz-Mercado H,Martinez-Castellanos MA,Hernandez-Rojas ML,et al.Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity.Retina,2008,28:19-25.
  • [7]The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. An international classification of retinopathy of prematurity Ⅱ:the classification of retinal detachment.Arch Ophthalmol,1987,105:906-912.
  • [8]The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity.Arch Ophthalmol,1984,102:1130-1134.
  • [9]An International Committee for the Classification of Retinopathy of Prematurity.The international classificatior of retinopathy of prematurity revisited.Arch Ophthalmol,2005,123:991-999.
  • [10]Law JC, Recchia FM, Morrison DG, et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.J AAPOS,2010,14:6-10.
  • [11]Hard AL, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment-a review. Acta Paediatr,2011.10:1-5.
  • [12]Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol,2008,246:1061-1063.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn